Trial Profile

A Phase II, Randomized, Open Label, Multi-center Design Study of Toripalimab Given Before and After Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; Carboplatin; Paclitaxel
Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

04 Jun 2024 Results(Between September 2019 and July 2020, n=46) evaluating the efficacy and safety of combining induction and consolidation toripalimab (a PD-1 inhibitor) with CRT ,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
19 Feb 2021 Status changed from recruiting to suspended as combination arm developed significant poor prognosis.
17 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com